Welcome to Paid Research Studies




  • Conditions:   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Lymphoid Leukemia;   Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Relapsed Acute Lymphoblastic Leukemia
    Intervention:   Drug: CPX-351
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Jazz Pharmaceuticals
    Not yet recruiting

  • Conditions:   Kidney Medullary Carcinoma;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Doxorubicin;   Drug: Gemcitabine;   Drug: Ixazomib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: CPX-351;   Procedure: Research skin biopsy;   Procedure: Research blood draw;   Procedure: Research bone marrow aspirate
    Sponsors:   Washington University School of Medicine;   Jazz Pharmaceuticals
    Not yet recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Atovaquone;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Drug: Gemtuzumab Ozogamicin
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   William Marsh Rice University
    Not yet recruiting

  • Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Elevated Alpha-Fetoprotein;   Hepatoblastoma;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: FDA-approved drug or combination of drugs;   Drug: FLAG induction;   Drug: 7 + 3 induction;   Drug: Low-dose cytarabine;   Other: Supportive care alone;   Device: Computational biology simulations software
    Sponsors:   University of Florida;   Gateway for Cancer Research;   Cellworks Group Inc.
    Not yet recruiting

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: glasdegib;   Drug: daunorubicin + cytarabine;   Drug: azacitidine;   Drug: Placebo;   Drug: cytarabine;   Procedure: HSCT
    Sponsor:   Pfizer
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute;   Leukemia, Relapsed Adult Acute Myeloid;   Myelodysplastic Syndromes, Previously Treated
    Interventions:   Drug: CPX-351;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin;   Biological: Haplo-Cord Stem Cell Transplantation
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Condition:   Leukemia, Myeloid, Acute
    Intervention:   Drug: CPX-351
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Alvocidib;   Drug: Cytarabine;   Drug: Daunorubicin
    Sponsor:   Tolero Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Combination Product: ITMHA;   Drug: Idarubicin;   Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Erwinia asparaginase;   Drug: Sorafenib;   Drug: G-CSF;   Drug: Dexrazoxane;   Biological: Stem Cell Transplant
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Lymphoma
    Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Pegaspargase;   Drug: Erwinase®;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Blinatumomab;   Drug: Ruxolitinib;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Clofarabine;   Drug: Vorinostat;   Drug: Idarubicin;   Drug: Nelarabine
    Sponsors:   St. Jude Children's Research Hospital;   Bristol-Myers Squibb;   Incyte Corporation;   Shire
    Recruiting

  • Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated Recombinant L-Asparaginase Erwinia Chrysanthemi;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Angioimmunoblastic T-Cell Lymphoma;   CD30-Positive Neoplastic Cells Present;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Stage III Anaplastic Large Cell Lymphoma;   Stage IV Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia;   Adult Lymphoblastic Lymphoma;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Previously Untreated Acute Myeloid Leukemia
    Interventions:   Biological: Samalizumab (BAML-16-001-S1);   Biological: BI 836858 (BAML-16-001-S2);   Other: Laboratory Biomarker Analysis;   Drug: Daunorubicin (BAML-16-001-S1);   Drug: Cytarabine (BAML-16-001-S1);   Drug: Azacitidine (BAML-16-001-S2);   Drug: AG-221 (BAML-16-001-S3);   Drug: Azacitidine (BAML-16-001-S3);   Drug: Entospletinib (BAML-16-001-S4);   Drug: Azacitidine (BAML-16-001-S4);   Drug: Entospletinib (BAML-16-001-S5);   Drug: Decitabine (BAML-16-001-S5);   Drug: Entospletinib (BAML-16-001-S6);   Drug: Azacitidine (BAML-16-001-S6);   Drug: Daunorubicin (BAML-16-001-S6);   Drug: Cytarabine (BAML-16-001-S6);   Drug: Pevonedistat (BAML-16-001-S9);   Drug: Azacitidine (BAML-16-001-S9);   Drug: AG-120 (BAML-16-001-S16);   Drug: Azacitidine (BAML-16-001-S16)
    Sponsor:   Beat AML, LLC
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphocytic Leukemia;   Acute Myeloid Leukemia
    Intervention:   Drug: Daunorubicin
    Sponsor:   Tara Lin
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
    Interventions:   Drug: Guadecitabine;   Other: Treatment Choice
    Sponsor:   Astex Pharmaceuticals
    Recruiting

  • Condition:   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Selinexor
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   Central Nervous System Leukemia;   Ph-Like Acute Lymphoblastic Leukemia;   Testicular Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Childhood B Acute Lymphoblastic Leukemia;   KMT2A Gene Rearrangement;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
    Interventions:   Drug: 75 approved agents;   Other: COXEN
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Leukemia
    Interventions:   Drug: Chemotherapy;   Drug: Quizartinib;   Drug: Placebo
    Sponsor:   Daiichi Sankyo, Inc.
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Leukemia, Acute Myeloid;   Myeloid Leukemia, Acute;   Leukemia, Myeloid, Acute;   Acute Myelogenous Leukemia;   Leukemia, Acute Myelogenous;   Myelogenous Leukemia, Acute
    Interventions:   Drug: Iomab-B;   Drug: Conventional Care;   Procedure: HCT
    Sponsor:   Actinium Pharmaceuticals
    Recruiting

  • Conditions:   Newly Diagnosed Acute Myeloid Leukemia (AML);   Untreated AML;   AML Arising From Myelodysplastic Syndrome (MDS);   AML Arising From Antecedent Hematologic Disorder (AHD);   AML Arising After Exposure to Genotoxic Injury
    Interventions:   Drug: AG-120;   Drug: AG-221;   Drug: cytarabine;   Drug: daunorubicin;   Drug: idarubicin;   Drug: mitoxantrone;   Drug: etoposide
    Sponsors:   Agios Pharmaceuticals, Inc.;   Celgene Corporation
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: MLN9708;   Drug: Cytarabine;   Drug: Daunorubicin
    Sponsors:   Massachusetts General Hospital;   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Genetic: Genetic Variation Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Childhood Acute Myeloid Leukemia;   Childhood Myelodysplastic Syndrome;   Cytopenia;   Down Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm;   Trisomy 21;   Trisomy 21 Mosaicism
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Entospletinib;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Decitabine;   Drug: Azacitidine
    Sponsor:   Gilead Sciences
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia (ALL)
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: PEG-asparaginase;   Drug: Vincristine;   Drug: Intrathecal (IT) Methotrexate;   Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate);   Drug: 6-Mercaptopurine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin
    Sponsors:   Amgen;   Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator;   Innovative Therapies For Children with Cancer Consortium
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Gilteritinib;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Daunorubicin
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting

  • Conditions:   Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: liposomal cytarabine-daunorubicin CPX-351;   Other: laboratory biomarker analysis
    Sponsors:   Rondeep Brar;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PEG-Asparaginase;   Drug: Methotrexate;   Drug: 6-MP (6-Mercaptopurine);   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Leucovorin;   Drug: Dexamethasone;   Other: Blood draw;   Device: CT/PET scans
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Shire;   Duke University;   Weill Medical College of Cornell University;   Lehigh Valley Health Network
    Recruiting